ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two antibody development deals were struck last week. In one, Abbott Laboratories will gain access to Protein Design Labs' technology for antibody humanization. Abbott is already a comarketer with MedImmune of the respiratory disease drug Synagis, a humanized antibody that was developed with PDL technology. Separately, Icos has licensed five monoclonal antibody candidates from Raven Biotechnologies. Abbott and Icos will make undisclosed payments to their partners.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X